), a leading health care products company, recently introduced the
Viance Crossing Catheter and Enteer Re-entry System in the U.S.,
the European Union and certain selected international markets.
These devices are used for endovascular treatment of chronic total
occlusions (CTOs) in peripheral arteries. The company announced
this news at the Cardiovascular and Interventional Radiological
Society of Europe ("CIRSE 2012") Annual Congress.
BARD C R INC (BCR): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis
To read this article on Zacks.com click here.
These specially designed innovative tools enable surgeons to bypass
difficult endovascular abrasions with enhanced precision. Its
unique balloon technology in the re-entry system allows better
maneuvering within the vessel.
The Viance Crossing Catheter and Enteer Re-entry System are
expected to boost Covidien's Vascular products portfolio under the
Medical Devices segment. In the last reported quarter, Vascular
product sales jumped 14% to $418 million, backed by outstanding
growth across peripheral vascular and neurovascular offerings.
These devices, together, are expected to further advance Covidien's
market-dominating peripheral products portfolio.
Covidien is a leading developer, manufacturer and distributor of
medical devices and services on a global scale. Its business
segments overlap with the business of its competitors such as
Becton, Dickinson and Company
Johnson and Johnson
CR Bard Inc.
) among others.
Covidien remains committed to rolling out new products and
technologies, focusing on emerging markets, and boosting market
share in core segments through investments in sales and marketing
infrastructure. In recent times, the company launched a number of
new products such as the HALO90 ULTRA, V-Loc, Nellcor Bedside SpO2
Patient Monitoring System, and the iDrive Ultra to leverage its
Management expects that focus on product innovation, aggressive
portfolio management and optimal spending on future investments
will yield positive results in the long run.
However, sustained pricing/procedure volume pressure, fluctuating
foreign exchange rates, a sluggish U.S. and European economy
represent major headwinds. We currently have a Neutral
recommendation on Covidien, which carries a short-term Zacks #3
Rank (Hold rating).